Systemic lupus erythematosus one disease or many?

被引:156
作者
Agmon-Levin, N. [1 ]
Mosca, M. [2 ]
Petri, M. [3 ]
Shoenfeld, Y. [1 ,4 ]
机构
[1] Chaim Sheba Med Ctr, Dept Med B, Zabludowicz Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel
[2] Univ Pisa, Rheumatol Unit, I-56100 Pisa, Italy
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA
[4] Tel Aviv Univ, Incumbent Laura Schwarz Kip Chair Res Autoimmune, Tel Aviv, Israel
关键词
Systemic lupus erythematosus; Genetics; Environmental factors; Classification criteria; Personalized medicine; ANTIPHOSPHOLIPID SYNDROME; REVISED CRITERIA; FEATURES; CLASSIFICATION; ANTIBODIES; COMPLEMENT; DEFICIENCY; PROJECT; LESSONS;
D O I
10.1016/j.autrev.2011.10.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Systemic lupus erythematosus (SLE) characterizes by a variety of clinical manifestations and the presence of a wide profile of autoantibodies. This clinical and serological heterogeneity raised the question: is SLE a single disease with varied phenotypes, or a similar phenotype shared by different diseases with diverse pathogenic mechanisms? Herein we debate the clinical, genetic, hormonal and serological differences typically observed in SLE on the one hand, and the numerous similarities between subtypes of this disease on the other. Leading to the conclusion that SLE may be considered not as a single disease but rather as a single syndrome, which defines by a set of signs, symptoms, or phenomena that occur together and suggest a particular abnormality. Additionally, the accumulated knowledge on gene expression pathways, autoantibodies clusters, hormonal and environmental factors associated with SLE may allow a better classification of this syndrome and updating of SLE criteria. This may further allow targeted biologics and other therapies as well as "personalized medicine" to begin. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:593 / 595
页数:3
相关论文
共 27 条
[11]  
GREENWALD RA, 1992, J RHEUMATOL, V19, P1490
[12]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[13]   Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus [J].
Hoffman, IEA ;
Peene, I ;
Meheus, L ;
Huizinga, TWJ ;
Cebecauer, L ;
Isenberg, D ;
De Bosschere, K ;
Hulstaert, F ;
Veys, EM ;
De Keyser, F .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (09) :1155-1158
[14]  
HUGHES GRV, 1985, CLIN EXP RHEUMATOL, V3, P285
[15]   Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease [J].
Kirou, KA ;
Lee, C ;
George, S ;
Louca, K ;
Peterson, MGE ;
Crow, MK .
ARTHRITIS AND RHEUMATISM, 2005, 52 (05) :1491-1503
[16]   Infections and autoimmunity - friends or foes? [J].
Kivity, Shaye ;
Agmon-Levin, Nancy ;
Blank, Miri ;
Shoenfeld, Yehuda .
TRENDS IN IMMUNOLOGY, 2009, 30 (08) :409-414
[17]  
Korb LC, 1997, J IMMUNOL, V158, P4525
[18]   Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice [J].
Mosca, M. ;
Tani, C. ;
Aringer, M. ;
Bombardieri, S. ;
Boumpas, D. ;
Cervera, R. ;
Doria, A. ;
Jayne, D. ;
Khamashta, M. A. ;
Kuhn, A. ;
Gordon, C. ;
Petri, M. ;
Schneider, M. ;
Shoenfeld, Y. ;
Smolen, J. S. ;
Talarico, R. ;
Tincani, A. ;
Ward, M. M. ;
Werth, V. P. ;
Carmona, L. .
AUTOIMMUNITY REVIEWS, 2011, 10 (07) :383-388
[19]   Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus [J].
Petri, M. ;
Singh, S. ;
Tesfasyone, H. ;
Dedrick, R. ;
Fry, K. ;
Lal, P. G. ;
Williams, G. ;
Bauer, J. W. ;
Gregersen, P. K. ;
Behrens, T. W. ;
Baechler, E. C. .
LUPUS, 2009, 18 (11) :980-989
[20]   Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients [J].
Sherer, Y ;
Gorstein, A ;
Fritzler, MJ ;
Shoenfeld, Y .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2004, 34 (02) :501-537